Research & Innovation
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- St. Luke's
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Meet our Team
- Why Choose Us
-
Current Trials
- Back
- Current Trials
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric Cancer Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
- Heart and Vascular
- Trauma and Critical Care
- Neurosciences
- Gastroenterology
- Orthopedics
- Gynecology
- Pulmonary Medicine
- Infectious Diseases
- Wound Care
- Internal Medicine
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- GME Data Outcomes
- Post Doctoral Research Fellowship
- Research Volunteer Program
- Institutional Review Board
- About Us
-
Clinical Trials
- Back
- Clinical Trials
- Why Choose Us
-
Current Trials
- Back
- Current Trials
- Gastroenterology
- Heart and Vascular
- Infectious Diseases
- Internal Medicine
- Neurosciences
-
Oncology
- Back
- Oncology
-
Clinical Trials
- Back
- Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric / Esophageal Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- St. Luke's
- About Oncology Trials
- Glossary of Terms
- St. Luke's
- Orthopedics
- Pediatrics
- Pulmonary Medicine
- Trauma and Critical Care
- Women’s Health
- Wound Care
- St. Luke's
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
- St. Luke's
- GME Data & Outcomes
- Post Doctoral Research
- Research Volunteer Program
-
Institutional Review Board
- Back
- Institutional Review Board
- IRB Membership
- Resident and Fellow Data Request Form
- How do I submit to the IRB
- Policy on Case Reports
- Policy on Multicenter Retrospective Data Sharing
- Fee Schedule
- Policies & Procedures Manual
- Cayuse Tutorial
- Internal Academic Research Study Approval Signature Form
- Forms
- Request for Central IRB Form
- FAQs
- Contact Us
- St. Luke's
- St. Luke's
- 1-866-STLUKES
Breast Clinical Trials
Agendia FLEX
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX).
Study Coordinator
Helen McGunnigle
email: Helen.McGunnigle@sluhn.org
phone: 484-658-5044
Close
Treatment Agent: N/A
Synopsis: You have been asked to consider taking part in this registry because you are being treated for stage I, stage II,or stage III breast cancer. If you participate, your doctor will receive the results of the Agendia Breast Cancer Suite (MammaPrint and BluePrint).
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only and the results will not be made available for use in your current breast cancer management.
- MammaPrint, an FDA cleared test, is used clinically to determine your risk for distant metastasis.
- BluePrint provides physicians with more information about their patient’s unique tumor biology.
- DiscoverPrint will allow the study of new gene associations and additional biomarkers that may be found to be relevant to breast cancer therapy and diagnosis.
- Breast cancer with different biological properties may respond different to certain therapies.
Close
- Is ≥18 years of age, at the time of signing the informed consent
- Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female) - New primary lesion - Eligible for chemo and endocrine therapy
Close
Alliance A071701
Genomically-Guided Treatment Trial in Brain Metastases (NCT03994796)
Close
This is a Phase 2 study evaluating the efficacy of a CDK, PI3K, or NTRK/ROS1 inhibitor in patients with progressive brain metastases from solid tumors harboring the alterations predicting sensitivity to each of these inhibitors.
Close
-
Histologically confirmed parenchymal metastatic disease to the brain from any solid tumor
-
Tissue must be available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy). If extracranial tissue is not available or there is no evidence of extracrania disease, brain metastasis tissue is sufficient for eligibility
-
Measurable CNS disease (≥ 10mm) that is new or progressive after systemic therapy or prior radiotherapy
-
Patients must be able to undergo MRI with contrast
-
Presence of clinically actionable alteration in NTRK, ROS1, CDK pathway or PI3K pathway in both a brain metastais and extracranial site per central review
-
For HER2+ breast cancer, patients must have received prior HER-2 directed therapy in the metastatic setting
-
For TNBC, patients must have had at least one chemotherpy in the metastatic setting
-
For ER and/or PR+ HER2- breast cancer, patients must have had at least one endocrine therapy in the metastatic setting
-
For melanoma, patietnts must have progressed after immunotherapy or after BRAF/MEK inhibitors for BRAF+ disease
-
For lung cancer, patients must have failed EGFR therapies for EGFR mutated disease
-
No known current diffuse leptomeningeal involvement
-
No surgery within 2 weeks prior to or after registration
-
No chemotherapy within 14 days prior to registration
Close
Eli Lilly J2J-MC-JZLH
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (NCT 05514054).
Study Coordinator
Helen McGunnigle
email: Helen.McGunnigle@sluhn.org
phone: 484-658-5044
Close
The purpose of this research study is to see how safe an investigational drug (Imlunestrant) is and how well it will work to help people with estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. Imlunestrant is a selective estrogen receptor degrader (SERD) and therefore should stop or slow down tumor growth in ER+ cancers.
Close
- Patients must have ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis
- Patients must have undergone definitive loco-regional therapy (surgery, with or without radiation therapy, and/or systemic therapy where appropriate per guidelines) of the primary index breast tumor(s)
- Patients must have received at least 24 months but no more than 60 months of any adjuvant ET, from time of adjuvant ET initiation to signing of ICF
- Prior (neo)adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor is allowed
- Patients may not have had more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET, may not have completed or discontinued prior adjuvant ET > 6 months prior to screening, and may not have had prior SERD therapy
- Patients may not receive concurrent exogenous reproductive hormone therapy
Close
GE-380-401
Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy.
Study Coordinator
Carolyn Seith
email:
Carolyn.Seith@sluhn.org
phone: 484-658-1789
Close
This study will evaluate the use of the diagnostic imaging agent Fluoroestradiol F18, also called Cerianna, in patients with metastatic breast cancer who have progressive disease on first line hormonal therapy. Cerianna is approved for commercial use by the FDA in the United States. Cerianna is used together with PET/CT scans to take pictures of areas of the body to look for signs of disease. The goal of the study is to evaluate if Cerianna PET/CT scan is clinically useful in guiding your study doctor’s therapeutic management of your cancer by detecting the ER status of the breast cancer cells in your body.
Close
- Female patients ≥ 18 years old
- Post-menopausal or pre-menopausal with known primary breast tumor(s) expressing ER in ≥ 1% of tumor cells by IHC
- Her2-negative (0, 1+, 2+ FISH negative) primary lesion
- Metastatic breast cancer with at least 1 identifiable lesion on standard of care imaging assessment, outside of the liver
- Progressive disease on 1st line hormonal therapy (AI) with or without a CDK4/6 inhibitor or mTOR inhibitor or PI3K inhibitor
- ECOG 0-2
- History of administered chemotherapy for metastatic disease is not allowed
- Isolated hepatic disease is not allowed
- 8 week washout from tamoxifen and 28 weeks from fulvestrant treatment is required
Close
NRG-BR007
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA trial) (NCT 04852887).
Study Coordinator
Helen McGunnigle
email: Helen.McGunnigle@sluhn.org
phone: 484-658-5044
Close
This study is being conducted to evaluate whether treatment with surgery and hormonal therapy for low-risk Stage I hormone sensitive, HER2-negative, breast cancer is as good as the usual treatment of surgery, radiation and hormonal therapy. In this study all participants must will take hormonal therapy for 5 years, some will receive radiation therapy in addition to the hormonal therapy.
Close
- Stage I, pT1N0M0 (≤ 2cm), HER2-negative, ER and/or PgR- positive breast cancer
- Unilateral invasive adenocarcinoma of the breast on histologic examination
- Patients must have undergone a lumpectomy and the margins must be histologically free of invasive tumor and DCIS (mastectomy is not allowed)
- Oncotype-DX recurrence score ≤ 18
- Patients with a T1a tumor (≤ 0.5 cm) do not have an Oncotype DX recurrence score previously documented, a tissue sample will be sent to the central lab for results prior to randomization
- Interval between last surgery for breast cancer and study entry must be no more than 70 days
- Bilateral mammogram or MRI required within 6 months prior to study entry
- Patients must be intending to take endocrine therapy for a minimum of 5 years (tamoxifen or AI), but CANNOT start endocrine therapy until AFTER enrollment on study
Close
Research
- Clinical Trials
- Why Choose Us
-
Current Trials
- Gastroenterology
- Heart and Vascular
- Infectious Diseases
- Internal Medicine
- Neurosciences
-
Oncology
-
Clinical Trials
- Biomarker Clinical Trials
- Bladder Clinical Trials
- Brain Clinical Trials
- Breast Clinical Trials
- Cervical Clinical Trials
- Colon Clinical Trials
- Colorectal Clinical Trials
- Gastric / Esophageal Clinical Trials
- Head and Neck Clinical Trials
- Leukemia Clinical Trials
- Liver Clinical Trials
- Lung Clinical Trials
- Lymphoma Clinical Trials
- Melanoma Clinical Trials
- Multiple Myeloma Clinical Trials
- Other Blood Cancer Clinical Trials
- Ovarian Clinical Trials
- Pancreatic Clinical Trials
- Prostate Clinical Trials
- Renal Clinical Trials
- Uterine Clinical Trials
- About Oncology Trials
- Glossary of Terms
-
Clinical Trials
- Orthopedics
- Pediatrics
- Pulmonary Medicine
- Trauma and Critical Care
- Women’s Health
- Wound Care
- Glossary of Terms
- Getting started with a Clinical Trial
- Intake Form
Interested in a
Clinical Trial?